Prognostic significance of morphological assessment of plasma cells in multiple myeloma

Neoplasma

Volumn 58, Issue 6, 2011, Pages 554-560

  Al Sahmani, M ^a,b   Trnavska, I ^a   Sevcikova, S ^b   Antosova, M ^a   Antosova, L ^a   Kissova, J ^a   Adam, Z ^a   Pour, L ^a,b   Nemec, P ^b   Greslikova, H ^b   Krejci, M ^a   Zahradova, L ^a   Bulikova, A ^a   Penka, M ^a   Hajek, R ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cytogenetics; Morphology; Multiple myeloma; Nucleus; Plasma cells; Prognostic significance

Indexed keywords

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW CELL; CANCER SURVIVAL; CHROMATIN; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEOLUS; OVERALL SURVIVAL; PLASMA CELL; PROGNOSIS; TREATMENT RESPONSE; BONE MARROW TRANSPLANTATION; CELL NUCLEUS; CLASSIFICATION; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TIME;

BONE MARROW TRANSPLANTATION; CELL NUCLEOLUS; CELL NUCLEUS; CHROMATIN; CYTOPLASM; DISEASE PROGRESSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84857495054     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_06_554     Document Type: Article

References (17)

1. SCUDLA V, ADAM Z. [Diagnostic importance and pitfalls of evaluating bone marrow smear preparation in multiple myeloma]. Vnitr Lek. 2006 Nov; 52 Suppl 2:55-65. Review. (In Czech).
2. ADAM Z, HÁJEK R, Mayer J, Ščudla V, Vorlíček J, editors. Multiple myeloma and other monoclonal gammopathies. Brno: Masarykova univerzita, 1999.
3. Hájek R., Ballová V. za CMG a SMS. Diagnostics and treatment of multiple myeloma-Recommendation of the Czech Myeloma Group and experts of the Slovak republic on diagnostics and treatment of multiple myeloma. Transfúze a hematologie dnes, 2009; 15 Suppl 2: 12-51.(In Czech).
4. FONSECA R, BERGSAGEL PL, DRACH J, SHAUGHNESSY J, GUTIERREZ N. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 2009, 23, 2210-2221. doi:10.1038/leu.2009.174
5. GOASGUEN JE, ZANDECKI M, MATHIOT C, SCHEIFF JM, BIZET M, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res, 1999 Dec; 23: 1133-40. doi:10.1016/S0145-2126(99)00132-0
6. GREIPP PR, RAYMOND NM, Kyle RA, O'Fallon WN. Multiple Myeloma: Significance of plasmablastic subtype in morphological classification. Blood, 1985; 65: 305-10.
7. GREIPP PR, LEONG T, BENNETT JM, GAILLARD JP, KLEIN B, et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood, 1998 Apr 1; 91: 2501-7.
8. TSUCHIYA J, MURAKAMI H, KANOH T, KOSAKA M, SEZAKI T, et al. Ten year survival and prognostic factors in multiple myeloma. Japan myeloma study group. Br J Haematol, 1994; 87: 832-4. doi:10.1111/j.1365-2141.1994.tb06745.x
9. Kačírková P, Campr V, editors. Hematooncological atlas of blood and bone marrow. Praha: Grada Publishing, 2007: 285.
10. KREJCI M, SCUDLA V, TOTHOVA E, SCHUTZOVA M, KOZA V. et al. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma 2009. Dec; 9: 436-42.
11. KREJCI M., HAJEK R., BUCHLER T., KRIVANOVA A., SVOBODNIK A. et al. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients. Neoplasma 2007; 54: 143-148. PMid:17319788
12. ADAM Z, KREJCI M, BACOVSKY J, HEJLOVA N, KUCA B, et al. Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W Czech Myeloma Group. Vnitr Lek 1998; 44: 400-408. PMid:9748876
13. MAYER J, STARÝ J, editors. Leukemie. Praha: Grada Publishing, 2002.
14. LEXOVÁ S. [Hematology for health care technicians]. 1st part, 1st edition, Brno, IDV PZ; 2000: 183. (In Czech).
15. AHMANN GJ, JALAL SM, JUNEAU AL, CHRISTENSEN ER, HANSON CA, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet, 1998; 01: 7-11 doi:10.1016/S0165-4608(97)00058-7
16. ZEMANOVA Z, MICHALOVA K, TAJTLOVA J, PAVLISTOVA L, OLTOVA A, et al. Molecular cytogenetic analysis of immunofluorescence-labeled plasma cells of patients with multiple myeloma enrolled in CMG 2002 clinical trial. Klinicka Onkologie 2008; 21 (S1): 204-206.
17. ROSS FM, Avetloiseau H, DRACH J, HERNANDEZ RIVAS JM, LIEBISCH P. European myeloma network recommendations for FISH in myeloma. Haematologica, 2007; 92 Suppl 2: 100-101. Abstract book of XI International Myeloma Workshop.